Anavex Life Sciences Q3 2024 Earnings Report

Anavex Life Sciences EPS Results

• Actual EPS: -$0.14
• Consensus EPS: -$0.15
• Beat/Miss: Beat by +$0.01
• One Year Ago EPS: -$0.14

Anavex Life Sciences Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Anavex Life Sciences Announcement Details

• Quarter: Q3 2024
• Date: 8/6/2024
• Time: Before Market Opens
• Conference Call Date: Tuesday, August 6, 2024
• Conference Call Time: 8:30AM ET

Anavex Life Sciences (NASDAQ:AVXL) Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company’s lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia. Anavex also holds ANAVEX3‐71, a muscarinic receptor agonist, in its pipeline for Rett syndrome and other developmental disorders. Through these programs, the company aims to demonstrate disease‐modifying effects by addressing underlying cellular dysfunction rather than solely managing symptoms.

Since its founding in 2012, Anavex has completed multiple Phase I and Phase II trials in North America and Europe, collaborating with academic research centers and contract research organizations to support its clinical development. The company has established manufacturing partnerships to ensure supply of clinical‐grade API and plans to expand its trial network into additional regions as programs advance. Christopher U. Missling serves as President and CEO, bringing more than two decades of experience in pharmaceutical research and development. Under his leadership, Anavex continues to explore strategic collaborations and funding opportunities to propel its pipeline toward regulatory milestones.

Anavex Life Sciences Q3 2024 Earnings Call Transcript

Key Takeaways

• Phase IIb/III Alzheimer’s data: Oral ANAVEX2-73 significantly slowed clinical decline in early Alzheimer’s patients with a favorable safety profile, and a marketing authorization application to the EMA is on track for Q4 2024.
• Interim analyses from the RNA-Seq study and the 96-week ATTENTION AD open‐label extension are expected in H2 2024, offering deeper insights into Alzheimer’s pathology and long‐term drug effects.
• Schizophrenia program momentum continues as the ANAVEX3-71 Phase 2 trial has completed dosing in cohort 1 and is nearing full enrollment in cohort 2 of Part A.
• Parkinson’s disease program will initiate a Phase 2b/3 trial in H2 2024, incorporating biomarkers to better understand drug effects on disease pathology.
• Strong financial position: Cash of $138.8 million, no debt, and an estimated four-year runway at current burn rate provide ample funding for ongoing programs.

Presentation

[Clint Tomlinson, Head of Investor Relations at Anavex Life Sciences]

At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. During the session, if you would like to ask a question, please use the Q&A box or raise your hand. Please note this conference is being recorded, and the call will be available for replay on Anavex's website at www.anavex.com. With us today is Dr. Christopher Missling, President and Chief Executive Officer, and Sandra Boenisch, Principal Financial Officer. Before we begin, please note that during this conference call, the company will make some projections and forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. We encourage you to review the company's filings with the SEC.

[Clint Tomlinson, Head of Investor Relations at Anavex Life Sciences]

This includes, without limitation, the company's Forms 10-K and 10-Q, which identify the specific factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. With that, I'd like to turn the call over to Dr. Missling.

[Christopher Missling, CEO at Anavex Life Sciences]

Thank you, Clint, and good morning, everyone. Thank you for being with us today to review our most recently reported financial results and to provide our quarterly business update. We continue to meaningfully advance our differentiated precision medicine clinical program, highlighted by the recent presentation of comprehensive results from the phase 2b/3 clinical trial, blarcamesine, Anavex 2-73, which were presented at the Alzheimer's Association International Conference, AAIC, showing that oral once-daily blarcamesine significantly slowed clinical decline for early Alzheimer's disease, patients with good comparative safety profile and no associated neuroimaging adverse events. Full data from the blarcamesine study in Alzheimer's disease phase 2b/3 placebo-controlled clinical trial will be published in an upcoming peer-reviewed journal. The initiated process for submitting a Marketing Authorisation Application, MAA, to the European Medicines Agency, EMA, under the centralized procedure is underway, with full regulatory submission of blarcamesine expected in Q4 of 2024.

[Christopher Missling, CEO at Anavex Life Sciences]

The marketing authorization would allow direct market access throughout the European Union for oral blarcamesine for the treatment of Alzheimer's disease. There are an estimated 7 million people in Europe with Alzheimer's disease, a number expected to double by 2030, according to the European Brain Council. Analysis of RNA sequencing, RNA-seq, which would reveal which genes are actively transcribed, or in other words, expressed in Alzheimer's patients, in comparison between placebo and blarcamesine of the placebo-controlled phase 2b/3 blarcamesine trial in early Alzheimer's disease, is underway. This data might have relevant value since it may provide insight into Alzheimer's disease pathology and how cells function in the presence of placebo or in the presence of blarcamesine, respectively. Interim data is expected in the second half of 2024. In June, we completed the last patient, last visit in the ATTENTION-AD open-label extension 96-week trial.

[Christopher Missling, CEO at Anavex Life Sciences]

Interim data from this trial is expected in the second half of 2024. The recent AAIC 2024 meeting resulted in constructive feedback, coupled with enthusiasm around our Alzheimer's disease program, strengthened by the recent addition of an experienced clinical team, which support Anavex future plans. Educational outreach will continue as we work towards MAA submission and beyond. We are also pleased to report that the clinical team continues to beat the planned timelines in the ongoing phase 2 clinical trial of Anavex 3-71 in schizophrenia patients. We have completed dosing of the first cohort and are nearing the completion of enrollment of the second cohort of schizophrenia patients in Part A of the trial.

[Christopher Missling, CEO at Anavex Life Sciences]

In Parkinson's disease, initiation of Anavex 2-73 phase 2b/3, an over six-month trial, including biomarkers, which we believe may be key for understanding drug effects on Parkinson's disease pathology and account for the recently changing context in the field of Parkinson's disease, is expected in the second half of 2024. In Rett syndrome, an educational presentation was provided at the 2024 IRSF Rett Syndrome Scientific Meeting, going from June 18 to June 19, 2024, which demonstrated the commitment of Anavex to the Rett syndrome community through direct engagement with patients and families. Positive and supportive feedback was received from families and investigators about the continued Anavex Rett syndrome program. Regarding Fragile X, new disease-specific, translatable, and objective biomarker data generated with Anavex 2-73, supporting the initiation of the Anavex 2-73 phase 2/3 clinical trial, was presented at the 19th NFXF International Fragile X Conference.

[Christopher Missling, CEO at Anavex Life Sciences]

Meeting with the NFXF leadership team strengthened Anavex's relationship with the community, coupled with an increased awareness of Anavex Fragile X syndrome program by engaging with patients and families in attendance. We are also expecting the initiation of Anavex 2-73 Phase 2/3 clinical trial in a new rare disease in the future. Finally, we are building medical affairs capabilities to expand education and physician support activities to ensure optimal medical impact, including continued clinical publications involving Anavex 2-73 and Anavex 3-71. And now, I would like to direct the call to Sandra Boenisch, Principal Financial Officer of Anavex, for our financial summary of the recently reported quarter.

[Sandra Boenisch, Principal Financial Officer at Anavex Life Sciences]

Thank you, Christopher, and good morning to everyone. I'm pleased to share with you today our third quarter financial results for our 2024 fiscal year. Our cash position at June 30th was $138.8 million, and we have no debt. During the quarter, we utilized cash and cash equivalents of $5.2 million in operating activities after taking into account changes in non-cash working capital accounts. At our current cash utilization rate, we believe we have a cash runway of approximately four years. During our most recent quarter, general and administrative expenses were $2.9 million, as compared to $2.8 million for the immediately preceding second quarter. Our research and development expenses for the quarter were $11.9 million, as compared to $9.7 million for the immediately preceding second quarter. And lastly, we reported a net loss of $12.2 million for the quarter, which is $0.14 per share.

[Sandra Boenisch, Principal Financial Officer at Anavex Life Sciences]

Thank you, and now back to you, Christopher.

[Christopher Missling, CEO at Anavex Life Sciences]

Thank you, Sandra. In summary, we remain dedicated to developing medicines for individuals suffering from brain disorders within neurodegenerative and neurodevelopmental disorders, which could further expand our differentiated precision medicine platform to deliver scalable treatments coupled with convenient oral dosing. I would now like to turn the call back to Clint for Q&A.

[Clint Tomlinson, Head of Investor Relations at Anavex Life Sciences]

Thank you, Christopher. We'll now begin the Q&A session. If you have a question, please raise your hand or enter it into the Q&A box. The first question comes from Tom Bishop, BI Research. Tom, you should be-

[Tom Bishop, Analyst at BI Research]

Hey, you hear me now?

[Clint Tomlinson, Head of Investor Relations at Anavex Life Sciences]

Yep. Great. Thanks, Tom.

[Tom Bishop, Analyst at BI Research]

Okay, I had a couple of questions. What are your plans to meet with the FDA or regulators in Asia, which you also alluded to recently, as you did earlier with EMA? And has a date been set for either, or is there some sort of a hold up or additional data you're waiting for?

[Christopher Missling, CEO at Anavex Life Sciences]

Thank you for the question. There's no hold up. There's only the focus right now on the EMA submission, which takes a lot of resources. We have to submit and put together a package of many modules, which can be so many pages and documents, so we focus on that. But the time will come, we don't know yet when, to also meet regulatory bodies around the world, including the agency in this country as well.

[Tom Bishop, Analyst at BI Research]

Oh, okay. With regards to the recent presentation at the AAIC, of the Phase 2/3 data, the question comes up with regard to varying number of patients included in different measures that the company presented. And I have assumed that it's just simply due to the fact that you can't force patients in the trial to come in and take certain tests, especially more invasive ones, and that this explains it. But of course, the dark side likes to claim cherry-picking. So can you discuss this aspect and put the issue to rest, you know, as to whether you do anything with the data that's given?

[Christopher Missling, CEO at Anavex Life Sciences]

May I understand better, you talk about the number of patients in each visit, scheduled visits?

[Tom Bishop, Analyst at BI Research]

in the different things like Cog 13 and whatever that you presented to the AAIC.

[Christopher Missling, CEO at Anavex Life Sciences]

Yeah, so the number of visit-

[Tom Bishop, Analyst at BI Research]

The number of patients from some of these-

[Christopher Missling, CEO at Anavex Life Sciences]

Time points

[Tom Bishop, Analyst at BI Research]

Do you understand?

[Christopher Missling, CEO at Anavex Life Sciences]

Visit time point. Yeah. So this is a... There is no other way to explain it, that every patient does not always present at the time point in question. He can skip, he can be impaired because of COVID, and this trial was during COVID. It's very normal. You just have to then always account for when you have a data point, and that's exactly described in the presentation. And when you look up other papers from Aduhelm, from lecanemab, donanemab, they are exactly the same. Every number is different at every time point because they are not always the same amount of patients attending the visit, so that's a very common procedure.

[Tom Bishop, Analyst at BI Research]

But you use the data exactly as given to you by the biostatistical firm, and who was that?

[Christopher Missling, CEO at Anavex Life Sciences]

Yeah, of course. There is no other way than to take every available data point. There is no other way to do that other than that.

[Tom Bishop, Analyst at BI Research]

Okay, and I wanted to clear up or confirm for myself the so-called, you know, the $150 million stock offering that the various news headlined, that was just a shelf offering to be used as needed opportunistically in the future, correct?

[Christopher Missling, CEO at Anavex Life Sciences]

So the company has been extremely cautious with financing. We've been very conservative. While other companies spent a ton of money, we've been very diligent on being very cautious with our, you know, fiscally responsible behavior. So what we did was just to make sure that one day in the future, when we do need more resources for market entry or other reasons, that we have that in place. So it's not meant to be used today or tomorrow, but the opportunity could arise, but it was just to put in place something so we have it in place for the future.

[Tom Bishop, Analyst at BI Research]

Okay, and regarding Rett, is there a date to initiate another Rett trial, or, well, I'm not sure what was going on there?

[Christopher Missling, CEO at Anavex Life Sciences]

So we have had very good feedback from the conference, as I mentioned, and there's no date yet, but we proceed, as we stated, to do a larger study for Rett syndrome as well.

[Tom Bishop, Analyst at BI Research]

Okay, and finally, with regards to Fragile X, was there a phase 1? You mentioned going to a phase 2b/3, I think, and

[Christopher Missling, CEO at Anavex Life Sciences]

The phase 1 was done with blarcamesine, with Anavex 2-73 already, so we can start into a phase 2 because of the phase 1 was already done prior to this, because of the drug was already tested in human healthy volunteers.

[Tom Bishop, Analyst at BI Research]

Okay, and actually, I had one more. With regards to schizophrenia, can you remind us a little more or explain the first cohort, the second cohort, part A?

[Christopher Missling, CEO at Anavex Life Sciences]

Yep.

[Tom Bishop, Analyst at BI Research]

Is there a part B? I mean, could you just run through that again?

[Christopher Missling, CEO at Anavex Life Sciences]

Sure. So part A is single ascending doses. So we test the tolerability and of the patients for the first doses, a lower dose and a higher dose subsequently, and the second higher dose is now almost completed enrollment. And the part B will be a longitudinal study run about, I think it's 28 days or so. So the drug will be given at the dose, which will be considered the best tolerated dose, and we will then observe patients over a longer period of time.

[Tom Bishop, Analyst at BI Research]

So the second dose is the higher dose?

[Christopher Missling, CEO at Anavex Life Sciences]

The second dose-

[Tom Bishop, Analyst at BI Research]

Yeah

[Christopher Missling, CEO at Anavex Life Sciences]

... from part A is the higher dose, and part B will be the dose which we choose.

[Tom Bishop, Analyst at BI Research]

Right

[Christopher Missling, CEO at Anavex Life Sciences]

... once it starts, and it will be a longer trial of 28 days or 4 weeks, basically.

[Tom Bishop, Analyst at BI Research]

All right. Thank you.

[Christopher Missling, CEO at Anavex Life Sciences]

Thank you.

[Clint Tomlinson, Head of Investor Relations at Anavex Life Sciences]

Thank you, Tom. Our next question comes from Soumit Roy at Jones Research.

[Soumit Roy, Analyst at Jones Research]

Good morning, everyone, and thank you for taking the question, and also congrats on executing on multiple fronts. On the AAIC data, Alzheimer's disease, could you give us a little color, make us understand on the dose dependency or the clear lack of dose dependency between 30 mg and 50 mg? There was ADAS-Cog working a little better for the 50 mg versus CDR-SB for the 30 mg. And the discontinuation rate, so what % of the 50 mg did you see had to scale back to 30 mg because of adverse events in the open-label extension?

[Christopher Missling, CEO at Anavex Life Sciences]

So let me talk, address the first question first. So the two arms are dose groups, and we use also the expression for that reason. When you read our description and the presentation, we talk about the dose groups, 30 mg dose group or 50 mg group. So since we allow titration to the best tolerated dose for those two arms, as well as the placebo, by the way, we basically realized that the end of the day, the target dose for most patients was relatively close to each other in those two arms. So while in the 50 mg group, there were some with 50 mg, there were also some with 30. So it was a bit higher than the 30 mg group, but not by much.

[Christopher Missling, CEO at Anavex Life Sciences]

So they're pretty much close, and that's why I also pre-specified the two arms together against placebo in a predefined analysis. So that was the background. So we have seen prior to that, a dose response curve in our phase 2a, so there's no doubt about it, the dose response is confirmed. But what we now notice is that in this trial where we... And that's coming to the second part of the question, where we notice, where we force patients to uptitrate to the target dose, 50, very quickly, within 2 weeks and then to 3 weeks, we noticed that didn't was very well received. Some patients had some dizziness, and they wouldn't feel comfortable about it. So because they are not impaired patients, they're early Alzheimer's, they felt saying, "Maybe we have COVID.

[Christopher Missling, CEO at Anavex Life Sciences]

I don't want to continue this." It was during the time of COVID, of course, as well. So that's why we had some dropouts at the higher dose, more than in the lower dose group. So what we now realize when we did the open label study, where we allowed a more, I would say, lenient and less stringent way of up-titration, in also allowing patients to take the drug at nighttime instead of in the morning, which we've basically forced patients to take during the trial early in the morning. So we noticed that there was much higher tolerance for either dose, 30 or 50, as long as they were allowed to get used to the drug for a longer period of time. And we noticed it also in the...

[Christopher Missling, CEO at Anavex Life Sciences]

In the compassionate use program, where there's extremely high tolerance with allowing patients to titrate to a, to 50 or 30, as long as they have enough time to do that, and then taking also nighttime dosing. So we don't see the adverse events we have seen in this trial, because we basically forced them to titrate so quickly up to the target dose. We also have to point out that it's actually a clearly manifestation of a manageable and addressable adverse event. It's not like, when you look at brain bleeding or brain swelling from the antibodies, which we don't have, that no matter how you take the drug, you always will have 30% or more of patients with that very dangerous side effects of a drug, of an antibody, which we don't have.

[Christopher Missling, CEO at Anavex Life Sciences]

But in our case, the adverse event of dizziness is a manageable one, because it just depended on the titration schedule, and that can be flexible, changed, and that's what we now will, of course, do in the future. So that's the answer to your question. And also, needless to say, that we are also, acknowledging that, and we've heard that from physicians, that the dizziness sign, again, not all patients had that, we also have to put this in perspective, that it's a sign that, shows penetration in the brain and shows that something's happening in the brain. Also, one last point I'd like to make, that this dizziness lasted really relatively short for those patients who had it. It was sometimes between 7-11 days in the average.

[Christopher Missling, CEO at Anavex Life Sciences]

So it's a very mild form of dizziness. So it's a very, you know, easy-to-address situation. But it shows up in this trial because, again, we forced patients to go to this high doses very quickly, and we learned the lesson that we can avoid that.

[Soumit Roy, Analyst at Jones Research]

That is really helpful, color. So the last question is, when should we expect the open-label 96-week data? Is it CTAD or more towards the end of the year? And should we expect after that data, you would approach the FDA with the entire packet submitted to European Authority, plus this open-label? Or if you can provide any details there.

[Christopher Missling, CEO at Anavex Life Sciences]

Yep. So let us first put together data together, but once we have it, we will make the decision. But all your suggestions could be valid recommendations.

[Soumit Roy, Analyst at Jones Research]

Thank you, and congratulations again on the progress.

[Christopher Missling, CEO at Anavex Life Sciences]

Thank you. I appreciate it.

[Clint Tomlinson, Head of Investor Relations at Anavex Life Sciences]

That's all the questions for now, Dr. Missling.

[Christopher Missling, CEO at Anavex Life Sciences]

Thank you. So in closing, we continue to focus on execution and commercial readiness as we advance our therapeutic pipeline to potentially improve patients' lives living with these devastating conditions. Thank you very much.

[Clint Tomlinson, Head of Investor Relations at Anavex Life Sciences]

Thank you, ladies and gentlemen. This concludes today's conference call. We appreciate your participation, and you can now disconnect.

Participants

Executives

• Christopher Missling, CEO
• Clint Tomlinson, Head of Investor Relations

Analysts

• Sandra Boenisch, Principal Financial Officer at Anavex Life Sciences
• Soumit Roy, Analyst at Jones Research
• Tom Bishop, Analyst at BI Research